Drugs for Volvulus of Midgut (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 7)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ivermectin |
Approved, Investigational, Vet_approved |
Phase 3 |
|
70288-86-7 |
6474909 |
Synonyms:
(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside
71827-03-7
AB00513813
AC1MJ4GR
AC1N7O27
BPBio1_000322
BRD-K24652731-001-02-7
BSPBio_000292
CHEMBL341047
CID11957587
CID4330618
CID6321424
CID6419971
CID6427057
EU-0100693
FT-0082656
HMS1568O14
HMS2089M09
I 8898
I8898_SIGMA
|
Ivermectin
IVERMECTIN
Ivermectina
Ivermectine
Ivermectinum
Lopac0_000693
MK-933
MLS001333247
MLS001333248
MLS002153248
MolPort-006-394-715
NCGC00094047-01
NCGC00094047-02
NCGC00094047-03
Prestwick_516
Prestwick2_000156
Prestwick3_000156
S1351_Selleck
SMR000857211
|
|
2 |
|
Azithromycin |
Approved |
Phase 2 |
|
83905-01-5 |
55185 447043 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside
121470-24-4
1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-,(2R-(2R*,3S*
75199_FLUKA
83905-01-5
9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A
AC-16014
AC1L9KEG
Aritromicina
Azadose
Azasite
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
azithromycin
Azithromycin
Azithromycin & Tumor Necrosis Factor
Azithromycin (AIDS Initiative)
Azithromycin (anhydrous)
Azithromycin dihydrate
Azithromycin monohydrate
Azithromycin Monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromax
Azitromicina
Azitromin
Azythromycin
Bayer brand OF azithromycin dihydrate
BIDD:GT0792
Bio-0676
BRN 5387583
BSPBio_002285
C38H72N2O12
CCRIS 1961
CHEBI:2955
CHEMBL529
CID447043
CP62,993
CP-62993
CPD000471864
DCH3
Dihydrate, azithromycin
DivK1c_000233
DRG-0104
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
HMS1922G12
|
HMS2094M11
HMS500L15
HSDB 7205
IDI1_000233
KBio1_000233
KBio2_000787
KBio2_003355
KBio2_005923
KBio3_001505
KBioGR_000731
KBioSS_000787
Lesvi brand OF azithromycin dihydrate
LS-1834
Mack brand OF azithromycin dihydrate
Misultina
MLS001055353
MLS001066331
MLS001201763
MLS001304005
MLS001332499
MLS001332500
MolPort-002-507-426
Monohydrate, azithromycin
NCGC00090753-01
NCGC00090753-02
NINDS_000233
NSC643732
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
SAM002589961
SMR000471864
SPBio_001544
Spectrum_000307
SPECTRUM1503679
Spectrum2_001582
Spectrum3_000653
Spectrum4_000186
Spectrum5_001867
Sumamed
Toraseptol
Tromix
Ultreon
UNII-JTE4MNN1MD
Vinzam
Vita brand OF azithromycin dihydrate
XZ-450
Zentavion
ZIT
Zithromac
Zithromax
Zithromax IV
Zithromycin
Zitromax
Zitromax Avium 600
Zmas
Zmax
Z-Pak
|
|
3 |
|
Rifampicin |
Approved |
Phase 2 |
|
13292-46-1 |
5458213 5381226 |
Synonyms:
13292-46-1
1-b]furan-21-yl acetate
3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin
3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV
3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV
3-(4-Methylpiperazinyliminomethyl)rifamycin SV
3-(4-Methylpiperazinyliminomethyl)-rifamycin SV
3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV
3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin
46713_FLUKA
46713_RIEDEL
62534-43-4
8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV
8-(4-Methylpiperazinyliminomethyl) rifamycin SV
8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin
8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv
8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv
83907_FLUKA
83907_SIGMA
8CI)
Abrifam
Archidyn
Arficin
Arzide
AZT + Rifampin
Ba 41166
Ba 41166/E
BA-41166E
Benemicin
Benemycin
BIDD:PXR0014
Bio-0621
BPBio1_000561
BSPBio_000509
C06688
C43H58N4O12
CAS-13292-46-1
CCRIS 551
CHEBI:28077
CHEBI:455936
CHEMBL180
CID5381226
CID5388984
CID5458213
CID5702112
CID6604339
CID6708473
CID6842115
CID6912767
CID6913622
CPD001906767
D00211
DB01045
Dione 21-acetate
Dipicin
DivK1c_000550
Doloresum
DRG-0109
EINECS 236-312-0
Eremfat
Famcin
Fenampicin
HMS1569J11
HMS1920P08
HMS2089F12
HMS2092G09
HMS501L12
HSDB 3181
KBio1_000550
KBio2_000919
KBio2_003487
KBio2_006055
KBio3_003018
KBioGR_001780
KBioSS_000919
L-5103
L-5103 Lepetit
LS-7689
MLS000028552
MLS001148237
MLS001333745
MolPort-000-767-051
MolPort-002-513-586
MolPort-003-666-281
MolPort-006-395-891
NCGC00016699-01
NCGC00017365-01
NCGC00018178-01
NCGC00022678-03
NCGC00022678-04
NCGC00022678-05
NCGC00160500-01
nchembio884-comp4
|
NCI60_000309
NINDS_000550
NSC 113926
NSC113926
NSC-113926
Piperine & Rifampicin
Prestwick_833
Prestwick0_000525
Prestwick1_000525
Prestwick2_000525
Prestwick3_000525
R/AMP
R0079
R3501_SIAL
R3501_SIGMA
R5777_SIGMA
R7382_SIGMA
Ramp
RAMP
R-Cin
Reserpine & Rifampicin
Rf
Rfamipicin
RFP
Rifa
Rifadin
Rifadin (TN)
Rifadin I.V
Rifadin I.V.
Rifadin Iv
Rifadin IV
Rifadin, Rimactane, Rifampicin, Rifampin
Rifadine
Rifagen
Rifaldazin
Rifaldazine
Rifaldin
Rifam
Rifamicin AMP
Rifamor
Rifampicin
Rifampicin & EEP
Rifampicin & Propolis
Rifampicin (JP15/INN)
Rifampicin [INN:BAN:JAN]
Rifampicin SV
Rifampicina
Rifampicina [INN-Spanish]
Rifampicine
Rifampicine [French]
Rifampicinum
Rifampicinum [INN-Latin]
rifampin
Rifampin
Rifampin (USP)
Rifampin [USAN]
Rifamsolin
Rifamycin
Rifamycin Amp
Rifamycin AMP
Rifaprodin
Rifcin
Rifinah
Rifobac
Rifoldin
Rifoldine
Riforal
Rimactan
Rimactane
Rimactane (TN)
Rimactazid
Rimactin
Rimactizid
Rimazid
Rimycin
RMP
Rofact
S1764_Selleck
SAM002264646
Sinerdol
SMR000058322
SMR000653525
SPBio_002430
Spectrum_000439
SPECTRUM1500529
Spectrum3_001837
Spectrum4_001250
Spectrum5_002018
STK080143
TNP00313
Tubocin
UNII-VJT6J7R4TR
WLN: V1 WQ A&1 E&1 E1UN- AT6N DNTJ D1
|
|
4 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
5 |
|
Antitubercular Agents |
|
Phase 2 |
|
|
|
6 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
7 |
|
Cola |
|
|
|
|
|
Interventional clinical trials:
(show all 14)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus |
Completed |
NCT00790998 |
Phase 3 |
Moxidectin;Ivermectin |
2 |
A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection |
Completed |
NCT00300768 |
Phase 2 |
2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin |
3 |
Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala |
Completed |
NCT00127504 |
Phase 2 |
Rifampin;Azithromycin |
4 |
A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection |
Withdrawn |
NCT01035619 |
Phase 2 |
moxidectin |
5 |
Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417 |
Unknown status |
NCT01880918 |
|
|
6 |
Different Clinicopathological Features of Non-Elderly Sigmoid Volvulus Patients |
Completed |
NCT04360525 |
|
|
7 |
Natural Orifice Specimen Extraction in Sigmoid Volvulus Patients |
Completed |
NCT04740619 |
|
|
8 |
Prenatal Ultrasound Screening of Intestinal Malrotation With a Higher Risk of Volvulus: Value of The Relative Position of The Superior Mesenteric Artery and Vein. Future of the Children With an Antenatal Malrotation Suspicion |
Completed |
NCT03356314 |
|
|
9 |
Best Management of Sigmoid Volvulus: A Prospective Randomized Trial |
Completed |
NCT01682395 |
|
|
10 |
Prenatal Diagnosis of Antenatal Midgut Volvulus: Specific Ultrasound Features |
Completed |
NCT03362450 |
|
|
11 |
Systematic Review of Isolated Hypoganglionosis and Presentation of a New Case Complicated With Sigmoid Volvulus |
Completed |
NCT04363125 |
|
|
12 |
a RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing â„¢ |
Completed |
NCT01301417 |
|
|
13 |
Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas |
Completed |
NCT03131401 |
|
|
14 |
Diagnostic Performance of Antenatal Ultrasound in the Localization of Intestinal Structures Involved in Malrotation With a Higher-risk of Volvulus |
Recruiting |
NCT03968107 |
|
|
|